Aligos Common Stock Shares Outstanding vs Other Assets Analysis

ALGS Stock

USD 25.51 2.52 10.96%

Aligos Therapeutics financial indicator trend analysis is way more than just evaluating Aligos Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aligos Therapeutics is a good investment. Please check the relationship between Aligos Therapeutics Common Stock Shares Outstanding and its Other Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Common Stock Shares Outstanding vs Other Assets

Common Stock Shares Outstanding vs Other Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aligos Therapeutics Common Stock Shares Outstanding account and Other Assets. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Aligos Therapeutics' Common Stock Shares Outstanding and Other Assets is -0.01. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Other Assets in the same time period over historical financial statements of Aligos Therapeutics, assuming nothing else is changed. The correlation between historical values of Aligos Therapeutics' Common Stock Shares Outstanding and Other Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Aligos Therapeutics are associated (or correlated) with its Other Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Assets has no effect on the direction of Common Stock Shares Outstanding i.e., Aligos Therapeutics' Common Stock Shares Outstanding and Other Assets go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Other Assets

Most indicators from Aligos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aligos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aligos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.At this time, Aligos Therapeutics' Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 3.82 in 2024, whereas Selling General Administrative is likely to drop slightly above 21.4 M in 2024.

	2022	2023	2024 (projected)
Depreciation And Amortization	3.7M	3.1M	3.2M
Interest Income	1.6M	1.2M	1.0M

Depreciation And Amortization Interest Income

Aligos Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.32	0.86	0.87	0.91	0.39	0.9	-0.26	0.54	-0.97	-0.6	0.25	0.98	0.39	-0.42	-0.16	0.99	0.76	-0.81	-0.69	-0.32	0.83	0.74	-0.61	0.91	0.5
Short Long Term Debt Total	-0.32		-0.46	-0.45	-0.43	0.22	-0.46	0.94	0.29	0.47	0.81	-0.22	-0.43	0.51	0.11	0.89	-0.36	-0.38	0.67	0.53	1.0	-0.31	-0.63	0.55	-0.43	-0.53
Other Current Liab	0.86	-0.46		0.98	0.93	-0.05	0.94	-0.55	0.47	-0.91	-0.84	0.27	0.91	0.3	-0.27	-0.24	0.84	0.89	-0.9	-0.88	-0.46	0.97	0.95	-0.81	0.93	0.83
Total Current Liabilities	0.87	-0.45	0.98		0.9	0.04	0.9	-0.52	0.59	-0.9	-0.84	0.47	0.9	0.31	-0.39	-0.18	0.85	0.95	-0.86	-0.84	-0.45	0.97	0.92	-0.76	0.9	0.84
Total Stockholder Equity	0.91	-0.43	0.93	0.9		0.11	1.0	-0.44	0.48	-0.93	-0.7	0.21	0.93	0.13	-0.49	-0.18	0.92	0.85	-0.79	-0.92	-0.43	0.87	0.89	-0.88	1.0	0.61
Other Liab	0.39	0.22	-0.05	0.04	0.11		0.1	0.4	0.44	-0.3	0.24	0.14	0.32	0.21	-0.53	0.18	0.43	-0.05	0.02	0.21	0.22	-0.09	-0.13	0.27	0.11	-0.43
Net Tangible Assets	0.9	-0.46	0.94	0.9	1.0	0.1		-0.49	0.44	-0.93	-0.73	0.18	0.93	0.1	-0.47	-0.23	0.91	0.83	-0.81	-0.93	-0.46	0.87	0.91	-0.89	1.0	0.63
Property Plant And Equipment Net	-0.26	0.94	-0.55	-0.52	-0.44	0.4	-0.49		0.24	0.45	0.89	-0.16	-0.42	0.44	0.01	0.83	-0.29	-0.42	0.71	0.6	0.94	-0.42	-0.74	0.61	-0.44	-0.7
Current Deferred Revenue	0.54	0.29	0.47	0.59	0.48	0.44	0.44	0.24		-0.43	-0.16	0.63	0.46	0.5	-0.67	0.58	0.51	0.66	-0.16	-0.34	0.29	0.55	0.37	-0.23	0.48	0.31
Net Debt	-0.97	0.47	-0.91	-0.9	-0.93	-0.3	-0.93	0.45	-0.43		0.73	-0.2	-1.0	-0.28	0.37	0.33	-0.98	-0.76	0.9	0.75	0.47	-0.85	-0.84	0.68	-0.93	-0.59
Retained Earnings	-0.6	0.81	-0.84	-0.84	-0.7	0.24	-0.73	0.89	-0.16	0.73		-0.38	-0.71	0.05	0.14	0.62	-0.59	-0.75	0.9	0.76	0.81	-0.77	-0.91	0.71	-0.7	-0.9
Accounts Payable	0.25	-0.22	0.27	0.47	0.21	0.14	0.18	-0.16	0.63	-0.2	-0.38		0.18	0.08	-0.55	0.14	0.23	0.64	-0.15	-0.22	-0.22	0.34	0.29	-0.16	0.21	0.43
Cash	0.98	-0.43	0.91	0.9	0.93	0.32	0.93	-0.42	0.46	-1.0	-0.71	0.18		0.3	-0.38	-0.3	0.98	0.75	-0.89	-0.74	-0.43	0.85	0.84	-0.67	0.93	0.58
Non Current Assets Total	0.39	0.51	0.3	0.31	0.13	0.21	0.1	0.44	0.5	-0.28	0.05	0.08	0.3		0.24	0.43	0.29	0.25	-0.21	0.11	0.51	0.45	0.0	0.22	0.13	0.22
Non Currrent Assets Other	-0.42	0.11	-0.27	-0.39	-0.49	-0.53	-0.47	0.01	-0.67	0.37	0.14	-0.55	-0.38	0.24		-0.24	-0.49	-0.49	0.05	0.44	0.11	-0.21	-0.36	0.42	-0.49	-0.01
Other Assets	-0.16	0.89	-0.24	-0.18	-0.18	0.18	-0.23	0.83	0.58	0.33	0.62	0.14	-0.3	0.43	-0.24		-0.2	-0.01	0.6	0.23	0.89	-0.09	-0.39	0.25	-0.18	-0.32
Cash And Short Term Investments	0.99	-0.36	0.84	0.85	0.92	0.43	0.91	-0.29	0.51	-0.98	-0.59	0.23	0.98	0.29	-0.49	-0.2		0.74	-0.8	-0.71	-0.36	0.79	0.75	-0.64	0.92	0.45
Common Stock Shares Outstanding	0.76	-0.38	0.89	0.95	0.85	-0.05	0.83	-0.42	0.66	-0.76	-0.75	0.64	0.75	0.25	-0.49	-0.01	0.74		-0.69	-0.83	-0.38	0.91	0.84	-0.77	0.85	0.81
Short Term Investments	-0.81	0.67	-0.9	-0.86	-0.79	0.02	-0.81	0.71	-0.16	0.9	0.9	-0.15	-0.89	-0.21	0.05	0.6	-0.8	-0.69		0.7	0.67	-0.83	-0.87	0.64	-0.79	-0.78
Non Current Liabilities Total	-0.69	0.53	-0.88	-0.84	-0.92	0.21	-0.93	0.6	-0.34	0.75	0.76	-0.22	-0.74	0.11	0.44	0.23	-0.71	-0.83	0.7		0.53	-0.81	-0.92	0.99	-0.92	-0.7
Capital Lease Obligations	-0.32	1.0	-0.46	-0.45	-0.43	0.22	-0.46	0.94	0.29	0.47	0.81	-0.22	-0.43	0.51	0.11	0.89	-0.36	-0.38	0.67	0.53		-0.31	-0.63	0.55	-0.43	-0.53
Other Current Assets	0.83	-0.31	0.97	0.97	0.87	-0.09	0.87	-0.42	0.55	-0.85	-0.77	0.34	0.85	0.45	-0.21	-0.09	0.79	0.91	-0.83	-0.81	-0.31		0.87	-0.73	0.87	0.85
Other Stockholder Equity	0.74	-0.63	0.95	0.92	0.89	-0.13	0.91	-0.74	0.37	-0.84	-0.91	0.29	0.84	0.0	-0.36	-0.39	0.75	0.84	-0.87	-0.92	-0.63	0.87		-0.87	0.89	0.84
Total Liab	-0.61	0.55	-0.81	-0.76	-0.88	0.27	-0.89	0.61	-0.23	0.68	0.71	-0.16	-0.67	0.22	0.42	0.25	-0.64	-0.77	0.64	0.99	0.55	-0.73	-0.87		-0.88	-0.64
Net Invested Capital	0.91	-0.43	0.93	0.9	1.0	0.11	1.0	-0.44	0.48	-0.93	-0.7	0.21	0.93	0.13	-0.49	-0.18	0.92	0.85	-0.79	-0.92	-0.43	0.87	0.89	-0.88		0.61
Property Plant And Equipment Gross	0.5	-0.53	0.83	0.84	0.61	-0.43	0.63	-0.7	0.31	-0.59	-0.9	0.43	0.58	0.22	-0.01	-0.32	0.45	0.81	-0.78	-0.7	-0.53	0.85	0.84	-0.64	0.61

Click cells to compare fundamentals

Aligos Therapeutics Account Relationship Matchups

Aligos Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	146.5M	265.3M	235.4M	146.7M	151.5M	193.1M
Short Long Term Debt Total	14.3M	13.0M	14.5M	12.6M	11.1M	10.6M
Other Current Liab	753K	14.1M	22.5M	12.9M	13.6M	11.7M
Total Current Liabilities	13.8M	30.3M	39.0M	33.1M	23.9M	27.1M
Total Stockholder Equity	(64.9M)	220.0M	184.7M	103.9M	92.1M	95.7M
Other Liab	3.6M	4.5M	133K	233K	209.7K	199.2K
Net Tangible Assets	(64.9M)	220.0M	184.7M	103.9M	119.5M	94.6M
Property Plant And Equipment Net	16.1M	14.9M	15.0M	12.5M	9.8M	11.1M
Current Deferred Revenue	6.8M	7.9M	7.6M	9.2M	1.3M	1.2M
Net Debt	(55.2M)	(207.4M)	(172.4M)	(68.8M)	(124.6M)	(130.8M)
Retained Earnings	(66.2M)	(174.7M)	(303.1M)	(399.1M)	(486.8M)	(462.5M)
Accounts Payable	3.8M	3.3M	3.0M	4.7M	2.5M	3.7M
Cash	69.6M	220.4M	186.8M	81.3M	135.7M	131.6M
Non Current Assets Total	26.3M	15.3M	30.9M	13.1M	10.4M	14.9M
Non Currrent Assets Other	188K	(3.3M)	866K	(2.5M)	625K	656.3K
Other Assets	188K	7.3K	866K	634K	(2.4M)	(2.3M)
Cash And Short Term Investments	117.7M	243.5M	190.7M	125.8M	135.7M	165.8M
Common Stock Shares Outstanding	21.9M	34.2M	39.9M	42.7M	24.9M	33.9M
Short Term Investments	48.1M	23.1M	3.9M	44.5M	(70K)	(66.5K)
Liabilities And Stockholders Equity	146.5M	265.3M	235.4M	146.7M	151.5M	193.1M
Non Current Liabilities Total	197.6M	15.0M	11.7M	9.7M	35.5M	51.1M
Capital Lease Obligations	14.3M	13.0M	14.5M	12.6M	11.1M	10.6M
Other Current Assets	2.0M	6.5M	13.7M	7.7M	5.4M	6.7M
Other Stockholder Equity	(180.7M)	395.0M	487.3M	502.6M	578.3M	308.4M
Total Liab	211.4M	45.3M	50.6M	42.8M	59.4M	70.8M
Net Invested Capital	(64.9M)	220.0M	184.7M	103.9M	92.1M	95.7M
Property Plant And Equipment Gross	16.1M	14.9M	22.2M	22.1M	20.6M	20.4M
Total Current Assets	120.2M	250.0M	204.4M	133.5M	141.1M	172.6M
Accumulated Other Comprehensive Income	(115K)	(188K)	452K	401K	545K	572.3K
Net Working Capital	106.4M	219.7M	165.5M	100.4M	117.2M	145.6M
Short Term Debt	2.5M	5.0M	5.8M	6.3M	6.5M	5.0M
Property Plant Equipment	16.1M	14.9M	15.0M	4.8M	4.3M	4.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC